Psychometric evaluation of the Functional Assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials

Quality of Life Research

Volumn 19, Issue 8, 2010, Pages 1215-1227

  Viala Danten, Muriel ^a   Dubois, Dominique ^b   Gilet, Hélène ^a   Martin, Silas ^c   Peeters, Katrien ^d   Cella, David ^e  

^a MAPI VALUES   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d Virco BVBA   (Belgium)

^e EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

FAHI questionnaire; Health Related Quality of Life; HIV AIDS; Psychometric properties

Indexed keywords

ADULT; ARTICLE; EVALUATION; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; FEMALE; HEALTH STATUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79951726513     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-010-9674-9     Document Type: Article

References (52)

1. Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., et al. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. The Journal of American Medical Association, 280(17), 1497-1503. (Pubitemid 28507402)
2. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338(13), 853-860. (Pubitemid 28135961)
3. Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., et al. (2006). The survival benefits of AIDS treatment in the United States. Journal of Infectious Diseases, 194(1), 11-19.
4. Mrus, J. M., Williams, P. L., Tsevat, J., Cohn, S. E., & Wu, A. W. (2005). Gender differences in health-related quality of life in patients with HIV/AIDS. Quality of Life Research, 14(2), 479-491. (Pubitemid 40576398)
5. van Sighem, A. I., van de Wiel, M. A., Ghani, A. C., Jambroes, M., Reiss, P., Gyssens, I. C., et al. (2003). Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS, 17(15), 2227-2236. (Pubitemid 37338896)
6. Agrawal, L., Lu, X., Jin, Q., & Alkhatib, G. (2006). Anti-HIV therapy: Current and future directions. Current Pharmaceutical Design, 12(16), 2031-2055. (Pubitemid 43821691)
7. Montessori, V., Press, N., Harris, M., Akagi, L., & Montaner, J. S. (2004). Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal, 170(2), 229-238. (Pubitemid 38134804)
8. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12(7), F51-F58. (Pubitemid 28190689)
9. Miller, J., Carr, A., Emery, S., Law, M., Mallal, S., Baker, D., et al. (2003). HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine, 4(3), 293-301. (Pubitemid 36949887)
10. Gulick, R. M. (1997). Current antiretroviral therapy: An overview. Quality of Life Research, 6(6), 471-474. (Pubitemid 27431702)
11. Leplege, A., Rude, N., Ecosse, E., Ceinos, R., Dohin, E., & Pouchot, J. (1997). Measuring quality of life from the point of view of HIV-positive subjects: The HIV-QL31. Quality of Life Research, 6(6), 585-594. (Pubitemid 27431712)
12. Reynolds, N. R. (2004). Adherence to antiretroviral therapies: state of the science. Current HIV Research, 2(3), 207-214. (Pubitemid 38854933)
13. Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., Aaronson, N., & ERIQA Group. (2002). Patient-reported outcomes: The example of health-related quality of life - A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209-238. (Pubitemid 34208219)
14. Lin, M. K., Wu, A. W., & Revicki, D. A. (2002). Incorporating quality of life measures in HIV clinical trials. HIC Clinical Trials, 3(3), 202-218. (Pubitemid 34704868)
15. Lohr, K. N., Aaronson, N. K., Alonso, J., Burnam, M. A., Patrick, D. L., Perrin, E. B., et al. (1996). Evaluating quality-of-life and health status instruments: Development of scientific review criteria. Clinical Therapeutics, 18(5), 979-992.
16. World Health Organisation. (1948). WHO definition of health. http://www.who.int/about/definition/en/print.html. Accessed 6 October 2009.
17. Clayson, D. J., Wild, D. J., Quarterman, P., Duprat-Lomon, I., Kubin, M., & Coons, S. J. (2006). A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. PharmacoEconomics, 24(8), 751-765. (Pubitemid 44232104)
18. Cella, D. F., McCain, N. L., Peterman, A. H., Mo, F., & Wolen, D. (1996). Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research, 5(4), 450-463.
19. Cella, D. F., Tulsky, D. S., Gray, G., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570-579. (Pubitemid 23071057)
20. Peterman, A. H., Cella, D., Mo, F., & McCain, N. (1997). Psychometric validation of the revised functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Quality of Life Research, 6, 572-584. (Pubitemid 27431711)
21. Wu, A. W., Rubin, H. R., Mathews, W. C., Ware, J. E., Jr., Brysk, L. T., Hardy, W. D., et al. (1991). A health status questionnaire using 30 items from the medical outcomes study. Preliminary validation in persons with early HIV infection. Medical Care, 29(8), 786-798.
22. Berzon, R. A., & Lenderking, W. R. (1998). Evaluating the outcomes of HIV disease: Focus on health status measurement. A publication for members of medical outcomes trust, 3(4).
23. Davis, E. A., & Pathak, D. S. (2001). Psychometric evaluation of four HIV disease-specific quality-of-life instruments. Annals of Pharmacotherapy, 35(5), 546-552. (Pubitemid 32428127)
24. Grossman, H. A., Sullivan, P. S., & Wu, A. W. (2003). Quality of life and HIV: Current assessment tools and future directions for clinical practice. AIDS Read, 13(12), 583-587.
25. Haubrich, R., Berger, D., Chiliade, P., Colson, A., Conant, M., Gallant, J., et al. (2007). Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS, 21(6), F11-F18. (Pubitemid 46568621)
26. Katlama, C., Esposito, R., Gatell, J. M., Goffard, J. C., Grinsztejn, B., Pozniak, A., et al. (2007). Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS, 21(4), 395-402.
27. Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet, 370(9581), 39-48. (Pubitemid 47017467)
28. Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 29-38. (Pubitemid 47017466)
29. Bonomi, A. E., Cella, D. F., Hahn, E. A., Bjordal, K., Sperner-Unterweger, B., Gangeri, L., et al. (1996). Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system. Quality of Life Research, 5(3), 309-320. (Pubitemid 26228464)
30. Eremenco, S. L., Cella, D., & Arnold, B. J. (2005). A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & The Health Professions, 28(2), 212-232. (Pubitemid 40628908)
31. Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16(3), 297-334.
32. Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc.
33. Hays, R. D., Anderson, R. T., & Revicki, D. A. (1998). Assessing reliability and validity of measurement in clinical trials. In M. J. Staquet, R. D. Hays, & P. M. Fayers (Eds.), Quality of life assessment in clinical trials: methods and practice (pp. 169-182). New-York, Tokyo: Oxford.
34. Hays, R. D., & Hayashi, T. (1990). Beyond internal consistency reliability: rationale and user's guide for Multitrait analysis program on the microcomputer. Behavior Research, Methods, Instruments and Computers, 22, 167-175.
35. Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol group. Annals of Medicine, 33(5), 337-343. (Pubitemid 32675374)
36. Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095-1108. (Pubitemid 127453463)
37. Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press.
38. Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials, 10(4), 407-415. (Pubitemid 20025670)
39. Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., Norman, G. R., & Clinical Significance Consensus Meeting Group. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77, 371-383. (Pubitemid 34260746)
40. Sloan, J. A., Symonds, T., Vargas-Chanes, D., & Fridley, B. (2003). Practical guidelines for assessing the clinical significance of health related quality of life changes within clinical trials. Drug Information Journal, 37, 23-31. (Pubitemid 37305150)
41. Wyrwich, K. W., Nienaber, N. A., Tierney, W. M., & Wolinsky, F. D. (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Medical Care, 37(5), 469-478.
42. Walters, S. J., & Brazier, J. E. (2005). Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Quality of Life Research, 14(6), 1523-1532. (Pubitemid 40848233)
43. Shikiar, R., Willian, M. K., Okun, M. M., Thompson, C. S., & Revicki, D. A. (2006). The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health and quality of life outcomes, 4, 71.
44. Yost, K. J., Sorensen, M. V., Hahn, E. A., Glendenning, G. A., Gnanasakthy, A., & Cella, D. (2005). Using multiple anchor-and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument. Value in Health, 8(2), 117-127. (Pubitemid 40525373)
45. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 20 May 2010.
46. Rao, D., Hahn, E. A., Cella, D., & Hernandez, L. (2007). The health related quality of life outcomes of English and Spanish speaking persons living with HIV/AIDS from the continental United States and Puerto Rico. AIDS Patient Care STDS, 21(5), 339-346. (Pubitemid 46842161)
47. Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIVinfected patients. Medical Care, 33(4 Suppl), AS173-AS182.
48. Schag, C. A., Ganz, P. A., Kahn, B., & Petersen, L. (1992). Assessing the needs and quality of life of patients with HIV infection: Development of the HIV overview of problems-evaluation system (HOPES). Quality of Life Research, 1(6), 397-413. (Pubitemid 23012622)
49. Call, S. A., Klapow, J. C., Stewart, K. E., Westfall, A. O., Mallinger, A. P., DeMasi, R. A., et al. (2000). Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research, 9(9), 977-985. (Pubitemid 32289935)
50. Murri, R., Fantoni, M., Del Borgo, C., Visona, R., Barracco, A., Zambelli, A., et al. (2003). Determinants of health-related quality of life in HIV-infected patients. AIDS Care, 15(4), 581-590. (Pubitemid 36871798)
51. Weinfurt, K. P., Willke, R. J., Glick, H. A., Freimuth, W. W., & Schulman, K. A. (2000). Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Medical Care, 38(4), 404-410.
52. Vidrine, D. J., Amick, B. C., I. I. I., Gritz, E. R., & Arduino, R. C. (2005). Assessing a conceptual framework of health-related quality of life in a HIV/AIDS population. Quality of Life Research, 14(4), 923-933. (Pubitemid 40685217)